Pazopanib for the treatment of renal cell carcinoma and other malignancies

Drugs of Today

Volumn 45, Issue 9, 2009, Pages 651-661

  Sonpavde, Guru ^a,b   Hutson, Thomas E ^a,c   Sternberg, Cora N ^d  

^a TEXAS ONCOLOGY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; AXITINIB; BEVACIZUMAB; BICALUTAMIDE; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; CYTOKINE; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; GEMCITABINE; INTERFERON; IRINOTECAN; LAPATINIB; PACLITAXEL; PAZOPANIB; PEMETREXED; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TIVOZANIB; TOPOTECAN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTERY THROMBOSIS; ASTHENIA; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; EPISTAXIS; FATIGUE; GLIOBLASTOMA; HAIR COLOR; HAIR DEPIGMENTATION; HAIR DISEASE; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTHYROIDISM; INSOMNIA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MOUTH ULCER; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RASH; REVIEW; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMATITIS; THYROID CANCER; UTERINE CERVIX CANCER;

EID: 75749151307     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2009.45.9.1424750     Document Type: Review

References (47)

1. Erber, R., Thurnher, A., Katsen, A.D. et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004, 18(2): 338-40.
2. Bergers, G., Song, S., Meyer-Morse, N. et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003, 111(9): 1287-95.
3. Motzer, R.J., Hutson, T.E., Tomczak, P. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27(22): 3584-90.
4. Escudier, B., Eisen, T., Stadler, W.M. et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27(20): 3312-8.
5. Llovet, J.M., Ricci, S., Mazzaferro, V. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359(4): 378-90.
6. Sonpavde, G., Hutson, T.E., Sternberg, C.N. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opin Investig Drugs 2008, 17(2): 253-61.
7. Sonpavde, G., Hutson, T.E. Pazopanib: A novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 2007, 9(2): 115-9.
8. Kumar, R., Knick, V.B., Rudolph, S.K. et al: Pharmacokinetic- pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007, 6(7): 2012-21.
9. Mendel D.B., Laird, A.D., Xin, X. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9(1): 327-37.
10. Wilhelm, S.M., Carter, C., Tang, L. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64(19): 7099-109.
11. Hu-Lowe, D.D., Zou, H.Y., Grazzini, M.L. et al. Nonclinical antiangiogenesis and antitumor activities of axitinlb (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008, 14(22): 7272-83.
12. Wedge, S.R., Kendrew, J., Hennequin, L.F. et al. AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005, 65(10): 4389-400.
13. Hurwitz, H.I., Dowlati, A., Saini, S. et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009, 15(12): 4220-7.
14. Rini, B.I. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. Cancer 2009, 115(10 Suppl.): 2306-12.
15. Hudes, G., Carducci, M., Tomczak, P. et al. Temsirolimus, Interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356(22): 2271-81.
16. Escudier, B., Pluzanska, A., Koralewski, P. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370(9605): 2103-11.
17. Rini, B.I., Halabi, S., Rosenberg, J.E. et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008, 26(33): 5422-8.
18. Motzer, R.J., Escudier, B., Oudard, S. et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372(9637): 449-56.
19. Sablin, M.P., Negrier, S., Ravaud, A. et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2009, 182(1): 29-34; discussion 34.
20. Rini, B.I., Michaelson, M.D., Rosenberg, J.E. et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal renal cell carcinoma. J Clin Oncol 2008, 26(22): 3743-8.
21. Rini, B.I., Wilding, G., Hudes, G. et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009, 27(27): 4462-8.
22. Tamaskar, I., Garcia, J.A., Elson, P. et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008, 179(1): 81-6.
23. Bhargava, P., Esteves, B., Lipatov, O.N. et al. Activity and safety of AV-951, a potent and selective VEGFR1, 2 and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial. Genitourinary Cancer Symposium. Orlando, Florida 2009, Abst 283.
24. Hutson, T.E. Davis, I.D., Machiels, J.P. et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomised discontinuation trial (RDT). J Clin Oncol 2007, 25(Suppl): Abst 5031.
25. Hutson, T.E., Davis, I.D., Machiels, J.H. et al. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multikinase angiogenesis inhibitor. J Clin Oncol 2008, 26(Suppl): Abst 5046.
26. Sternberg, C.N. Szczylik, C., Lee, E. et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2009, 27(Suppl.): Abst 5021.
27. FDA approves Votrient for advanced renal cell cancer. DailyDrugNews.com October 21, 2009.
28. Taylor, S.K., Chia, S., Dent, S. et al. A phase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma: Results after completion of stage I: A trial of the Princess Margaret Hospital Phase II Consortium. J Clin Oncol 2009, 27(Suppl.): Abst 1133.
29. Dejonge, M., Savage, S., Verweij, J. et al. A phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently. J Clin Oncol 2006, 24(Suppl.): Abst 3088.
30. Olaussen, K.A., Commo, F., Tailler, M. et al. Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines. Oncogene, advance online publication 14 September 2009.
31. Slamon, D., Gomez, H.L., Kabbinavar, F.F. et al. Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2- positive advanced or metastatic breast cancer. J Clin Oncol 2008, 26(Suppl.): Abst 1016.
32. Sleijfer, S., Ray-Coquard, I., Papai, Z. et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009, 27(19): 3126-32.
33. Maki, R.G., D'Adamo, D.R., Keohan, M.L. et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009, 27(19): 3133-40.
34. Demetri, G.D., van Oosterom, A.T., Garrett, C.R. et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006, 368(9544): 1329-38.
35. Zhang, L., Hannay, J.A., Liu, J. et al. Vascular endothelial growth factor overexpresslon by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance. Cancer Res 2006, 66(17): 8770-8.
36. Monk, B., Mas, L., Zarba, J.J. et al. A randomized phase II study: Pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L+P) in advanced and recurrent cervical cancer (CC). J Clin Oncol 2009, 27(Suppl.): Abst 5520).
37. Yau, C.C., Chen, P.J., Curtis, C.M. A phase I study of pazopanib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2009, 27(Suppl.): Abst 3561.
38. Brady, J., Middleton, M., Midgley, R.S. et al. A phase I study of pazopanib in combination with FOLFOX 6 or capeOx in subjects with colorectal cancer. J Clin Oncol 2009, 27(Suppl.): Abst 4133.
39. Altorki, N., Guarino, M., Lee, P. et al. Preoperative treatment with pazopanib (GW786034), a multikinase angiogenesis inhibitor in early-stage non-small cell lung cancer (NSCLC): A proof-of-concept phase II study. J Clin Oncol 2008, 26(Suppl.): Abst 7557.
40. Nikolinakos, P., Altorki, N., Guarino, M. et al. Analyses of plasma cytokine/angiogenic factors (C/AFs) profile during preoperative treatment with pazopanib (GW786034) in early-stage non-small cell lung cancer. J Clin Oncol 2008, 26(Suppl.): Abst 7568.
41. Frentzas, S.N., Groves, M.D., Barriuso, J. et al. Pazopanib and lapatinib in patients with relapsed malignant glioma: Results of a phase I/II study. J Clin Oncol 2009, 27(Suppl.): Abst 2040. 42. Bible, K.C., Smallridge, R.C., Maples, W.J. et al. Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers. J Clin Oncol 2009, 27(Suppl.): Abst 3521.
42. Friedlander, M., Hancock, K.C., Benigno, B. et at. Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results of a phase II study. J Clin Oncol 2007, 25(Suppl.) Abst 5561.
43. Prince, H.M., Honemann, D., Spencer, A. et al. Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: A phase 2 study of pazopanib (GW786034). Blood 2009, 113(19): 4819-20.
44. Podar, K., Tonon, G., Sattler, M. et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci USA 2006, 103(51): 19478-83.
45. Davids, M., Charlton, A., Ng, S.S. et al. Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma. J Clin Oncol 2009, 27(26): e97-100.
46. Tan, A.R., Jones, S.F., Dowlati, A. et al. Phase I study of the safety, tolerability, and pharmacokinetics (PK) of weekly paclitaxel administered in combination with pazopanib (GW786034). J Clin Oncol 2008, 26(Suppl.): Abst 3552.
47. Suttle, B., Jones, S., Dowlati, A. et al. Phase I study of the safety and pharmacokinetics (PK) of paclitaxel or paclitaxel with carboplatin administered in combination with pazopanib (GW786034). J Clin Oncol 2007, 25(Suppt.): Abst 14118.